Reg FD Disclosure

Securities and Exchange Commission (“SEC”), and the Company’s website (provectusbio.com) to disclose material financial and operational information to the Company’s shareholders, prospective investors, the media, and others interested in the Company.   The Company also intends to use certain social media accounts as a means of disclosing information and observations about the Company and its business, and for complying with the Company’s disclosure obligations under Regulation FD: the Provectus Substack account (provectus.substack.com), the @ProvectusBio Twitter account (twitter.com/provectusbio), and the Company’s LinkedIn account (linkedin.com/company/provectus-biopharmaceuticals). The information and observations that the Company posts through these social media channels may be deemed material. Accordingly, investors should monitor these social media channels in addition to following the Company’s press releases, SEC filings, and website. The social media channels that the Company intends to use as a means of disclosing the information described above may be updated from time to time. The Company will no longer provide information and observations using its emailed newsletter Provectus News.   Pursuant to the rules and regulations of the SEC, the information in this Item 7.01 disclosure is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended.         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Date: April 17, 2023     PROVECTUS BIOPHARMACEUTICALS, INC.                                            By: /s/ Heather Raines     Heather Raines, CPA     Chief Financial Officer (Principal Financial Officer)